Lifastuzumab vedotin Antibody
Lifastuzumab vedotin is an antibody-drug conjugate (ADC) targeting NaPi2b and delivering the cytotoxic payload MMAE to inhibit tubulin polymerization. It is a research tool for studying non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) in both in vitro and in vivo experimental models.
Product Specifications
Target
Sodium-dependent phosphate transporter, Antibody-Drug Conjugates (ADCs)
Clonality
Monoclonal
Conjugation
Unconjugated
Field of Research
Pharmacology & Drug Discovery
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC041820-500 1x 500 µL
Ep-CAM / CD326 (Epithelial Marker) (rVU-1D9), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400994-500 1x 500 µL
TNF alpha (J2D10), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470204-500 1x 500 µL
Complement C4d (C4D204), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040177-500 1x 500 µL
CD50 (ICAM-3) (101-1D2), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680525-500 1x 500 µL
CD63 (MX-49.129.5), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 